Pre-treatment Platelet Counts Associated With Prognosis in Stage 2-3 Rectal Cancer
Platelet counts at the time of initial diagnosis had prognostic value for patients with rectal adenocarcinoma receiving neoadjuvant treatment.
Platelet counts at the time of initial diagnosis had prognostic value for patients with rectal adenocarcinoma receiving neoadjuvant treatment.
A 4-microRNA signature is significantly associated with progression-free survival in patients with advanced melanoma treated with neoadjuvant ipilimumab.
Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).
Serum fibroblast growth factor 21 (FGF21) is useful as a diagnostic and prognostic biomarker in patients with clear cell renal cell carcinoma (ccRCC).
Bcl-2 family member (BIM) expression and phosphoinositide 3 kinase R1 (PIK3R1) might be candidate biomarkers for renal cell carcinoma (mRCC).
Metformin, a widely used oral anti-diabetic drug, enhanced the anti-prostate cancer activity of abiraterone and enzalutamide.
BRCA1 and AEG1 mRNA expression levels do not significantly impact median progression-free survival in non-small cell lung cancer (NSCLC).
Treatment with a single epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can no longer be considered adequate.